Trial Profile
A Substudy of the IBCSG 24-02/ SOFT Trial to Investigate Estrogen Suppression for Patients Participating in Arms B and C of the IBCSG 24-02/ SOFT Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Tamoxifen (Primary) ; Triptorelin (Primary)
- Indications Early breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms SOFT-EST
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 15 Mar 2019 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 15 Mar 2019 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2020.